证券日报网讯 2月12日，广济药业发布公告称，公司近日收到国家药品监督管理局核准签发的甲钴胺片 的《药品注册证书》，规格为10片/板×2板/盒，注册分类为化学药品4类，批准文号为国药准字 H20263341，用于周围神经病治疗。 （编辑 袁冠琳） ...

Group 1 - The core viewpoint is that Fudan Zhangjiang's stock performance is diverging between its A-share and Hong Kong share listings, with the Hong Kong stock showing significant gains due to favorable market conditions [1] - As of 09:37, Fudan Zhangjiang's Hong Kong stock (01349.HK) was priced at 3.36 HKD, reflecting a 3.38% increase, outperforming its A-share counterpart [1] - The trading activity in the Hong Kong market is robust, with a turnover rate of 0.10% and a transaction amount of approximately 1.04 million HKD [1] Group 2 - The healthcare sector in the Hong Kong stock market is performing well, with the medical-themed sector continuing to rise, and the Hong Kong Stock Connect medical ETF achieving four consecutive gains [2] - This positive sector performance has created a favorable atmosphere for Fudan Zhangjiang's Hong Kong shares [2] Group 3 - The company has made progress in innovative drug development, with its clinical trial application for FZ-P001 sodium, aimed at visualizing malignant lesions in known or suspected lung cancer patients during surgery, receiving acceptance notification [3] - This development may attract market attention towards the company's potential in the field of precision medicine [3]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with limited disruptions, and institutions are increasing their positions in innovative companies, maintaining a positive outlook on undervalued innovative targets [1][4] - The overall market sentiment has improved, driven by significant business development transactions, and the pharmaceutical sector is expected to continue its steady growth in 2026, despite potential short-term volatility [4][5] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, ranking second among 12 industry indices [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - Since Q4 2025, the proportion of domestic capital holding pharmaceutical stocks through Hong Kong Stock Connect has slightly decreased, while foreign capital holdings have increased [32] - As of February 10, 2026, domestic holdings were at 22.2%, down 0.2 percentage points, while foreign holdings rose to 39.7%, up 0.9 percentage points [32] Sales Performance - In 2025, China's pharmaceutical market sales decreased by 1% year-on-year, with public hospitals accounting for the largest market share at 10,977 billion RMB, down 2.1% [5] - Retail pharmacy sales reached 5,878 billion RMB, growing by 2.4%, with online pharmacies seeing a significant increase of 13.6% [5] National Procurement - The recent national procurement round had a high selection rate of 93%, with 1,020 products from 1,091 participating companies expected to be implemented by the end of March 2026 [5] - The procurement process has seen increased participation and a diverse range of selected products, ensuring stability in clinical demand [5] Investment Recommendations - The report recommends focusing on innovative drugs, particularly companies like Sanofi and Hengrui Medicine, which have rich catalysts and clear long-term growth logic [4] - It also suggests looking into CXO companies benefiting from high downstream demand and improving financing conditions, such as WuXi AppTec [4]

HRS-5346是恒瑞医药自主研发的口服小分子Lp(a)抑制剂，通过与阻断载脂蛋白(a)[apo(a)]和载脂蛋白B100（ApoB100）之间最初的非共价结合，从而抑制 二硫键和Lp(a)的形成，降低Lp(a)水平。研究结果显示，HRS-5346可有效降低Lp(a)，且安全性良好[3]。 近日，恒瑞医药子公司山东盛迪医药有限公司的HRS-5346用于治疗脂蛋白（a）水平的升高被国家药品监督管理局药品审评中心纳入突破性治疗品种名 单。 脂蛋白(a)[Lp(a)]水平升高是全球最普遍的单基因脂质疾病，是脂蛋白紊乱的典型表现之一。中国成年人的Lp(a)水平＞30mg/dL和50mg/dL的患病率分别为 18.67%和8.41%[1]。Lp(a)升高已被证实为动脉粥样硬化性心血管疾病（ASCVD）包括冠心病、缺血性脑卒中、外围血管疾病及钙化性主动脉瓣狭窄等疾 病的独立危险因素[2]。靶向Lp(a)的降脂疗法是心血管疾病防治的潜在新方向之一，但目前尚无针对降低Lp(a)适应症的治疗药物，该疗法仍处于临床研究 阶段。 近日，恒瑞医药子公司山东盛迪医药有限公司的HRS-5346用于治疗脂蛋白（a）水平的升高被国家药品监督 ...

Group 1 - The company emphasizes the importance of innovative drug research and talent development, indicating a strategic focus on these areas [2] - Multiple original first-class drugs are currently in orderly progress towards clinical trial stages, showcasing the company's commitment to innovation [2] - The company plans to continuously optimize its talent recruitment mechanism and allocate professional resources based on research and development progress [2]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with a high selection rate of 93%, indicating a positive outlook for innovative companies in the sector [4][5] - The market sentiment has improved, driven by significant business development (BD) transactions, suggesting a continuation of the positive trend in 2026 despite potential short-term volatility [4] - The report emphasizes the importance of focusing on fundamentals and valuations when selecting stocks, particularly undervalued innovative companies that have been overlooked during market fluctuations [4] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, outperforming the broader market [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - As of February 10, 2026, domestic institutional holdings through Hong Kong Stock Connect slightly decreased to 22.2%, while foreign holdings increased to 39.7%, indicating a shift towards more positive sentiment among foreign investors [32] - Key increases in holdings were noted in leading CXO companies benefiting from demand recovery, such as Tigermed and WuXi AppTec [37][38] Valuation Overview - The report provides a valuation summary for various companies, with notable buy ratings for AstraZeneca, BeiGene, and others, indicating strong growth potential [3] - The average price-to-earnings (P/E) ratio for the healthcare sector is reported at 28.4 times, with specific segments like biopharmaceuticals at 13.1 times [16] Sales Trends - The report notes a 1% year-on-year decline in China's pharmaceutical market sales for 2025, with significant variations across different sales channels [5] - Public hospitals accounted for the largest market share but experienced a 2.1% decline, while retail pharmacies saw a 2.4% increase, driven by online sales growth [5] Procurement Insights - The recent national procurement round involved 316 commonly used drugs, with a high participation rate and diverse product offerings, ensuring stable clinical supply [5] - The procurement process has been refined to enhance quality and reliability, with stricter requirements for participating companies [5]

Core Insights - Sanofi announced the appointment of Belén Garijo as the new CEO, effective after the annual shareholders' meeting on April 29, 2026 [1] - Current CEO Paul Hudson will end his term on February 17, 2026, and will not continue as a board member [1] - Belén Garijo previously served as CEO of Merck and is set to complete her term at Merck by the end of April 2026 [1]

Core Viewpoint - Shenzhen's Industrial and Information Technology Bureau has issued the "Shenzhen 'Artificial Intelligence +' Advanced Manufacturing Action Plan (2026-2027)", focusing on accelerating innovation and transformation in drug research and development, cell and gene therapy, and precision medical services [1] Group 1: Action Plan Objectives - The plan aims to promote technological innovation in key areas such as drug target discovery and validation, drug design, high-throughput drug screening, DNA-encoded compound library screening, computer-aided drug design, virtual screening, and gene locus screening related to drug therapy [1] - It supports the establishment of major platforms for AI-driven drug research and development, enhancing the integration of technological resources [1] Group 2: AI and Biotechnology Integration - The initiative emphasizes the deep integration of artificial intelligence and biotechnology (AI+BT) to accelerate advancements in the sector [1]

Core Viewpoint - Novo Nordisk (NVO.US) plans to increase investment in Ireland to produce an oral version of its popular weight loss drug Wegovy for markets outside the U.S. [1] Group 1: Investment Plans - The company will expand its production facility in Athlone, central Ireland, although the CEO did not disclose the scale of the investment [1]. - The investment in Ireland signifies the company's commitment to regaining its position in the weight loss market despite increasing price competition [1]. Group 2: Product Performance - Wegovy's oral version was launched in early January and has become one of the most successful drug launches in history, with over 240,000 patients in the U.S. currently using it [1]. - The oral drug is seen as a crucial tool for Novo Nordisk to close the gap with competitors like Eli Lilly (LLY.US) [1]. Group 3: Market Context - Ireland is recognized as a global hub for pharmaceutical manufacturing, with Eli Lilly also producing active ingredients for its weight loss and diabetes drugs there [1]. - The Irish economy is heavily reliant on U.S. investments and is currently under the spotlight due to tariff threats from former President Trump [1].

Group 1 - The annual report of Jiaying Pharmaceutical (002198) for the year 2025 is expected to be disclosed on April 28, 2026 [1] - The company's shareholding structure exhibits instability, with the largest shareholder holding a relatively low percentage of shares, which may lead to risks of changes in control [1]